
June 23 (Reuters) - Cidara Therapeutics Inc CDTX.O:
CIDARA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B NAVIGATE TRIAL EVALUATING CD388, A NON-VACCINE PREVENTATIVE OF SEASONAL INFLUENZA
CIDARA THERAPEUTICS INC - STUDY MEETS PRIMARY AND SECONDARY EFFICACY ENDPOINTS
CIDARA THERAPEUTICS INC - CD388 DOSES SHOW 76%, 61%, AND 58% PROTECTION FROM INFLUENZA
CIDARA THERAPEUTICS INC - CD388 WELL-TOLERATED WITH NO SAFETY SIGNALS OBSERVED